Guselkumab
TREMFYA
Interleukin-23 Antagonist
NADAC/unit
$7349.6703
No Shortage
Tier 1: 82.1%
PA Req: 407.3%
TREMFYA is an interleukin-23 antagonist indicated for the treatment of: adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with moderate-to-severe plaque psoriasis....
vs. brand TREMFYA: Generic saves up to -73397% per unit
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.